A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

960 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess whether there is a significant difference in visual outcomes or corneal haze after surface ablation for moderate and high myopia in active duty service members treated with PRK, Mitomycin-C (MMC) PRK and LASEK.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel

NCT00412568

Myopia

COMPLETED NA

Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel

NCT00413673

Myopia

COMPLETED NA

Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia

NCT00348049

Myopia

COMPLETED NA

Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism

NCT00365040

Refractive Errors

COMPLETED NA

Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatment

NCT04698174

Ametropia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MODERATE AND HIGH MYOPIA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

LASEK- laser-assisted subepithelial keratectomy

Group Type ACTIVE_COMPARATOR

MMC PRK

Intervention Type PROCEDURE

mitomycin C PRK

3

Mitomycin C PRK

Group Type ACTIVE_COMPARATOR

LASEK

Intervention Type PROCEDURE

LASEK

1

PRK- Photorefractive keratectomy

Group Type ACTIVE_COMPARATOR

PRK

Intervention Type PROCEDURE

PRK

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRK

Intervention Type PROCEDURE

MMC PRK

mitomycin C PRK

Intervention Type PROCEDURE

LASEK

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed consent.
2. Normal, healthy, active duty adults age 21 years or older. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
3. Manifest refractive spherical equivalent of greater than -4.00 diopters (D) up to -10.00 D.
4. Best spectacle corrected visual acuity of 20/20 or better in both eyes.
5. Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
6. Both eyes must fall in the same refraction group and there must be less than 1 D difference between eyes.
7. Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian.
8. Access to transportation to meet the follow-up requirements.
9. Available for evaluation during the 1-year follow-up period.
10. Consent of the subject's command to participate in the study.

Exclusion Criteria

1. Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Women of childbearing age will take a urine pregnancy test before starting this study.
2. Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as keratoconus, iritis, uveitis, keratoconjunctivitis sicca, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
3. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
4. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
5. Any physical or mental impairment that would preclude participation in any of the examinations.
6. Prior refractive or ocular surgery.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes